Int J Infect Dis:多学科讨论:手术路径中优化抗菌药处方能解决抗菌药耐药问题吗?

2017-09-27 王淳 环球医学

迄今为止,关于手术抗菌药处方的研究主要集中在术前,在很大程度上仅限于预防、住院患者和SSI。2017年7月,发表在《Int J Infect Dis》的一项由英国、南非和印度科学家进行的研究,考察了手术路径中如何改善抗菌药使用的系统水平。



迄今为止,关于手术抗菌药处方的研究主要集中在术前,在很大程度上仅限于预防、住院患者和SSI。2017年7月,发表在《Int J Infect Dis》的一项由英国、南非和印度科学家进行的研究,考察了手术路径中如何改善抗菌药使用的系统水平。请看本期多学科讨论组临床药师各抒己见为您梳理本文看点——

手术路径(手术前、中和后)中优化抗生素处方是解决抗生素耐药性重要驱动因素的一个关键方面,并且能同时降低全球感染的负担。仅在英国,每年有1000万名患者经历手术,相当于每年住院患者中有60%需要手术干预。绝大多数手术过程需要有效给予有限的抗生素以防止感染。来自世界各地的证据表明手术预防的抗生素是无效的,或者在术后不适当的持续时间内被延长。无效的抗生素预防可能导致手术部位感染(SSI),是一个重大的全球疾病负担。世界卫生组织估算手术患者的术后SSI率高达50%(取决于手术类型),尤其在低和中等收入国家。在这些国家中,SSI是最常报道的健康护理相关感染。在欧洲医院中,SSI仅占全部健康护理相关感染的19.6%。许多手术感染管理的科学研究与感染预防、手术室控制、手术预防和SSI管理相关,许多研究针对术后30日内的感染。但是值得注意的是,SSI仅代表多种术后感染类型之一。本文概述了手术路径并考虑感染管理和每步路径的抗生素处方。本文的目的是识别研究的意义和系统改善的机会。

多学科讨论记实:

本研究证实了优化整个手术途径的抗菌药处方是解决抗菌药耐药性重要驱动因素的关键,研究要点为:1、来自世界各地的证据表明,用于手术预防的抗菌药无效;2、许多手术感染管理中的证据与感染预防和控制、手术预防以及SSI的管理相关;3、概述了手术路径并考虑感染管理和每步路径的抗生素处方。

世界卫生组织(WHO)最近出版了预防SSI的指南,对预防SSI提供了详细和循证的建议,包括手术抗菌药预防。该指南建议延长超出外科手术的抗菌药预防措施以预防SSI。此外,WHO建议全球监测SSI作为任何预防和控制感染计划的关键组成部分。但是,SSI监督通常执行不力,实践中存在不一致之处,包括监督类型、持续时间和质量。

研究人员对密歇根匹兹堡干预措施的实施情况进行了广泛的回顾,以预防英国重症监护病房血液感染。研究人员报告说,当地文化对干预结局非常重要。此外,据报道,最成功的医疗机构通过将干预措施同当地环境适当地结合来推动和实施预防。在手术中,一个关键步骤是更好地与外科医生接触,并将他们纳入抗菌药管理计划。随着抗菌药耐药性驱动的威胁越来越大,迫切需要了解如何最大限度地减少感染负担,并优化整个手术途径的抗菌药使用。

抗菌药使用方面的干预措施往往仅考虑、解决患者途径这一个点,其注意力主要集中在预防性抗菌药的使用上。而多种干预措施有可能影响手术患者的感染相关结局。需要从社会科学的视角去探索在手术中使用抗菌药的文化背景决定因素,这有可能提供可持续改善质量和手术安全的措施。识别和绘制不同医疗机构中当前的外科行为者和行为,能针对当地患者人群的具体情况进行干预,并确保在全球范围内手术安全实施的平等性。

原始出处:

Natalie Schellack, et al. A situational analysis of current antimicrobial governance, regulation and utilisation in South Africa. International Journal of Infectious Diseases, 2017.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2012425, encodeId=0c37201242544, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Feb 12 23:05:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807580, encodeId=fd70180e5804b, content=<a href='/topic/show?id=ec2b80423ef' target=_blank style='color:#2F92EE;'>#耐药问题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80423, encryptionId=ec2b80423ef, topicName=耐药问题)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Tue May 01 23:05:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330607, encodeId=fcf9133060e1d, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Sep 29 08:05:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373037, encodeId=fbb613e303767, content=<a href='/topic/show?id=eb2555e176c' target=_blank style='color:#2F92EE;'>#抗菌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55717, encryptionId=eb2555e176c, topicName=抗菌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Fri Sep 29 08:05:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439871, encodeId=12b014398e1b7, content=<a href='/topic/show?id=35904318480' target=_blank style='color:#2F92EE;'>#多学科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43184, encryptionId=35904318480, topicName=多学科)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Sep 29 08:05:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2012425, encodeId=0c37201242544, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Feb 12 23:05:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807580, encodeId=fd70180e5804b, content=<a href='/topic/show?id=ec2b80423ef' target=_blank style='color:#2F92EE;'>#耐药问题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80423, encryptionId=ec2b80423ef, topicName=耐药问题)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Tue May 01 23:05:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330607, encodeId=fcf9133060e1d, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Sep 29 08:05:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373037, encodeId=fbb613e303767, content=<a href='/topic/show?id=eb2555e176c' target=_blank style='color:#2F92EE;'>#抗菌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55717, encryptionId=eb2555e176c, topicName=抗菌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Fri Sep 29 08:05:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439871, encodeId=12b014398e1b7, content=<a href='/topic/show?id=35904318480' target=_blank style='color:#2F92EE;'>#多学科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43184, encryptionId=35904318480, topicName=多学科)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Sep 29 08:05:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2012425, encodeId=0c37201242544, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Feb 12 23:05:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807580, encodeId=fd70180e5804b, content=<a href='/topic/show?id=ec2b80423ef' target=_blank style='color:#2F92EE;'>#耐药问题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80423, encryptionId=ec2b80423ef, topicName=耐药问题)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Tue May 01 23:05:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330607, encodeId=fcf9133060e1d, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Sep 29 08:05:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373037, encodeId=fbb613e303767, content=<a href='/topic/show?id=eb2555e176c' target=_blank style='color:#2F92EE;'>#抗菌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55717, encryptionId=eb2555e176c, topicName=抗菌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Fri Sep 29 08:05:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439871, encodeId=12b014398e1b7, content=<a href='/topic/show?id=35904318480' target=_blank style='color:#2F92EE;'>#多学科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43184, encryptionId=35904318480, topicName=多学科)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Sep 29 08:05:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2012425, encodeId=0c37201242544, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Feb 12 23:05:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807580, encodeId=fd70180e5804b, content=<a href='/topic/show?id=ec2b80423ef' target=_blank style='color:#2F92EE;'>#耐药问题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80423, encryptionId=ec2b80423ef, topicName=耐药问题)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Tue May 01 23:05:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330607, encodeId=fcf9133060e1d, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Sep 29 08:05:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373037, encodeId=fbb613e303767, content=<a href='/topic/show?id=eb2555e176c' target=_blank style='color:#2F92EE;'>#抗菌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55717, encryptionId=eb2555e176c, topicName=抗菌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Fri Sep 29 08:05:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439871, encodeId=12b014398e1b7, content=<a href='/topic/show?id=35904318480' target=_blank style='color:#2F92EE;'>#多学科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43184, encryptionId=35904318480, topicName=多学科)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Sep 29 08:05:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-29 lhlxtx
  5. [GetPortalCommentsPageByObjectIdResponse(id=2012425, encodeId=0c37201242544, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Feb 12 23:05:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807580, encodeId=fd70180e5804b, content=<a href='/topic/show?id=ec2b80423ef' target=_blank style='color:#2F92EE;'>#耐药问题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80423, encryptionId=ec2b80423ef, topicName=耐药问题)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Tue May 01 23:05:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330607, encodeId=fcf9133060e1d, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Fri Sep 29 08:05:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373037, encodeId=fbb613e303767, content=<a href='/topic/show?id=eb2555e176c' target=_blank style='color:#2F92EE;'>#抗菌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55717, encryptionId=eb2555e176c, topicName=抗菌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Fri Sep 29 08:05:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439871, encodeId=12b014398e1b7, content=<a href='/topic/show?id=35904318480' target=_blank style='color:#2F92EE;'>#多学科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43184, encryptionId=35904318480, topicName=多学科)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Sep 29 08:05:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]

相关资讯

Nat Rev Urol:手术金标准时代,局部消融治疗肾癌还有空间吗?

以肾部分切除术为代表的肾脏手术切除至今仍是肾癌治疗的金标准。随着局部消融技术的日趋完善,该疗法与手术治疗之间的关系是相互竞争还是互为补充?美国福克斯癌症中心泌尿肿瘤科Serge Ginzburg教授对此进行了一项综述,并于9月12日在线发表于《Nature Reviews Urology》上。

J Surg Oncol:根治性前列腺切除术后尿失禁修复术的全国性的和基于人群的研究

最近,有研究人员进行了旨在评估根治性前列腺切除术(RP)后尿失禁(PPI)手术的使用情况和调查了该手术使用相关的因素。群体研究是在瑞典男性前列腺癌数据库(PCBaSe)中进行的,这些病人是在1998年和2012年年间进行初次的RP。PPI修正术过程在病人注册处进行鉴定。另外,研究人员还评估了PPI外科手术的风险比(HR)和95%的置信区间(CIs)。研究发现,26280名男性中的782名(3%)男

女子生死关头,家属拒绝手术!人民医院这样做!

这是9月23日中午,发生在海南省乐东县人民医院的抢救现场。一宫外孕破裂出血的女子,生命危在旦夕。当医生向患者及其丈夫说明病情需立即手术挽救生命时,让所有人意想不到的一幕发生了。患者本人同意手术治疗,但其丈夫却坚决反对,把在场的医务人员骂了个遍,要求转院到三亚,并做出过激行为。反复沟通无效。按照患者的病情,如果转院到三亚,最大的可能性是死在前往医院的路上。眼瞅着患者的生命体征越来越弱,科室马上向医院

肝癌没法手术亦可局部治疗, “海扶超声”隔着肚皮烧死肿瘤

中国肝癌的发病率一直位居恶性肿瘤榜的前五位,而死亡率则高居第二位。大多数患者在肝癌确诊时已进展为中晚期,其手术切除率较低,而术后复发率高,术后5年复发率高达70%。因此及早发现,选择合适的治疗手段至关重要。近些年,出现了一个新的肝癌局部治疗方法——高强度聚焦超声消融治疗,简称“HIFU”,俗称“海扶”,因为无创也能穿透入体内,杀死肿瘤达到“隔山打牛”的效果而引起关注。肝癌局部治疗手段有哪些两年前,

软组织肿物手术后反复发作 手术方式如何抉择?

49岁女性,右大腿软组织肿物手术后反复发作4年半。软组织肉瘤的诊断需要临床、影像学、病理相结合。对于临床表现、影像学表现与病理结果不相符的病例,特别需要注意。如何进行明确诊断?

中国手术机器人已开展4万余例手术,全球忙3台都在中国

装有手术钳的机械臂伸缩,其中的芯片自动传输数据,记录完成的手术量。根据设在上海的长海医院手术机器人国际培训中心提供的数据,从2006年引进首台手术机器人至今年2月,我国已累计开展4万余例机器人手术,机器人走上手术台已成为现实。然而,当你真正躺在病床上,是否会有这样的担心,电压不稳它会乱挥刀吗?万一程序被黑客入侵……“全球最忙手术机器人在中国”南昌大学第一附属医院泌尿外科病房中,69岁的罗丹做机器人